Nxera Pharma Secures Exclusive Rights to Fabry Disease Phase 3 Oral Therapy Candidate Lucerastat for Japan and Selected Asia Pacific Markets

Tokyo, Japan and Cambridge, UK, 28 October 2026 – Nxera Pharma Co., Ltd. ("Nxera" or the "Company"; TSE: 4565) today announces that it has exercised its option to license lucerastat from Idorsia Ltd ("Idorsia"; SIX: IDIA) and has entered into a co-development and commercialization agreement (the "Agreement"). Under the Agreement, Nxera will hold exclusive rights to develop and commercialize lucerastat in Japan, South Korea, Taiwan and selected other Asia Pacific markets, excluding China (the "Territory").